Biological Study Of Oxaliplatin Liposomes

Oxaliplatin is used to treat colon cancer and liver cancer that has s pread. However, the clinical use of anti-cancer drug oxaliplatin is s everely limited by its toxicity and side effects. Objective:Anti-canc er drug oxaliplatin wasencapsulated to targeted organ by using lipos omes as drug carriers, and the drug carrier liposomes was modified with targeting to increase the therapeutic effect of anticancer drugs, while reducing the anti-cancer drugs systemic side effects. Methods:To study preparation technology, formulas, characters, targeting and pharmacokinetics regularity of common,long-circulating,long circulat ing thermosensitive and long circulating magnetic liposomes. Results: Oxaliplatin common liposome was prepared by reverse phase evap oration. And theoptimal preparation technology of oxaliplatin comm on liposome is 100 mg/mL phospholipids, the ratio of drug:phosph olipids is 1:40, the time taking ultrasound is 6 min, the ratio of ph ospholipids:cholesterol is 4:1, the average encapsulation efficiency of oxaliplatin lipisomes is 35.0%±2.5%, the particle diameter of bla nk liposome is 88.2nm, the particle diameter of oxaliplatin liposome s is 175.1 nm. Targeting efficiency of oxaliplatin long circulating m agnetic liposome group is about 76.5%. Conclusions:Oxaliplatin co mplex liposome was easily prepared for industry, and could increas e markedly the targeting organ, but decrease system toxicity and si de effects.